You are here

Programme at a Glance - 55th EASD Annual Meeting

Non-commercial satellite symposia on the occasion of the 55th EASD Annual Meeting:

Tuesday,
17 Sept 2019
Hype and hope for prevention of type 2 diabetes
07:30 - 08:30, Sols Hall
 

55th EASD Annual Meeting Scientific Programme:

Tuesday, 17 September 2019

 Joslin HallVilanova HallOchoa HallServet HallTrueta HallSerrano-Rios HallSols Hall
08:30
08:45
Opening Ceremony      
08:45
09:15
Presidential Address      
09:15
10:00
51st Claude Bernard Lecture      
10:15
11:45
OP 1OP 2OP 3OP 4OP 5OP 6 
12:00
13:00
Poster Event A (12:00 - 13:00, Poster Hall)
CREDENCE 

 Lessons from the DynaHEALTH consortium: Bio-psychosocial model of glycaemic health

   

EASD e-Learning

(12:00 - 14:00)

13:15
14:15
Beijing Community Diabetes Study (BCDS)Results from the Anti-CD3 mAb (teplizumab) prevention trialThe PIONEER journey: from concept to successful oral peptide delivery   
Poster Event B (13:15 - 14:15, Poster Hall)
14:30
16:00
OP 7OP 8OP 9OP 10OP 11OP 12 
16:15
16:55
34th Camillo Golgi Lecture Rising Star Symposium    
16:55
17:15
13th Albert Renold Lecture    
17:15
17:55
     

18:10
19:10

     

EASD General Assembly - Discussions and Questions

 

 

Thursday, 19 September 2019

 Joslin HallVilanova HallOchoa HallServet HallTrueta HallSerrano-Rios HallSols HallMaimónides Hall
08:30
10:00
Incretin based medication: current state and future developmentsHyperglycaemia in pregnancy: treatment and risk for mother and childNew data from the Restoring Insulin Secretion (RISE) StudyDiabetologia Symposium: Developmental origin of diabetesIs type 2 diabetes produced by precocious senescence?Targeting liver may have an impact on glycaemia?  
10:15
11:45
OP 25OP 26OP 27OP 28OP 29OP 30  
12:00
13:00
Poster Event E (12:00 - 13:00, Poster Hall)
CONCLUDEUnique features and findings of the long-term REWIND (Researching cardiovascular Events with a Weekly INcretin in Diabetes) trial Innovative technologies in obesity and type 2 diabetes discovery and treatment  

EASD e-Learning

(12:00 - 14:00)

EFSD / AstraZeneca Mentorship Presentation

(12:00 - 14:30)

13:15
14:15
Results and implications of CAROLINA (CARdiOvascular Safety of LINAgliptin) comparing linagliptin vs glimepirideProteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuria: (PRIORITY) study    
Poster Event F (13:15 - 14:15, Poster Hall)
14:30
16:00
OP 31OP 32OP 33OP 34OP 35OP 36  
16:15
17:00

Induction of Honorary Members

54th Minkowski Lecture

       
17:15
18:15
Diabetes in primary careDialogue between clinical chemistry and diabetologyMichael Berger debate: The emphasis on sedentary behaviour as lifestyle intervention target is entirely warrantedReactive metabolites in mechanisms of insulin resistanceThe many faces of type 2 diabetesDiabetes and the brain: from mice to man  

 

View the Industry Symposia Programme here.